The MarketReader Minute
đź’Š IBB Slips; Incyte Jumps on Strong Q2, Exelixis Drops on Sales Miss | Biotech Sector Insights
(IBB) edged down 0.2% Tuesday as mixed earnings and interest rate uncertainty weighed on sentiment. While the FDA's approval of SEPHIENCE™ for phenylketonuria marked a sector win, underperformance from MRNA, EXEL, IQV, CRSP, and BNTX dragged on the ETF.